Friday, 27 May 2022
  
Login

Australia's most trusted
source of pharma news

Friday, 27 May 2022
News

Sanofi cancer drug expands

Posted 27 January 2022 AM

Sanofi was among a few companies that slipped through new indications for their therapies before the end of 2021, again pushing forward its PD-1 inhibitor Libtayo.

A TGA update detailing new or extended uses registered in December reveals it took only 43 working days to provisionally approve Libtayo for treatment of adults with a type of skin cancer called metastatic basal cell carcinoma (BCC) while it granted full registration for patients with locally advanced disease.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (9)

Sales & Customer Relations (38)

Access & Reimbursement (4)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (5)

Devices (2)

Other (28)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.